News Akeso, Inc.

Equities

9926

KYG0146B1032

Market Closed - Hong Kong S.E. Other stock markets 04:09:09 2024-04-25 am EDT			5-day change	1st Jan Change
48.45 ^HKD	+2.11%		+6.72%	+4.42%

Apr. 24	Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	MT
Apr. 24	National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	Apr. 24	MT
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	Apr. 23	CI
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	Mar. 25	AQ
Akeso to Raise Over HK$1 Billion Via Share Sale	Mar. 22	MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	Mar. 18	MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC	Mar. 06	CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	Mar. 05	MT
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	Mar. 04	CI
Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy	Feb. 23	MT
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	Feb. 15	RE
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024	Feb. 15	AQ
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3%	Feb. 08	MT
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference	Feb. 08	AQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023	Feb. 08	AQ
Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI	Jan. 23	CI
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap	Jan. 08	PR
Akeso, Inc. Announces Innovative Clinical Development Roadmap	Jan. 08	CI
Chinese Medical Regulator Accepts Akeso’s Supplemental New Drug Application for Gastric Cancer Therapy	Jan. 04	MT
Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer	Jan. 04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Akeso, Inc.

Equities

9926

KYG0146B1032

Summary

Filters